Ipamorelin dosage, strictly as the studies report it — what was given, to whom, by which route.

Read this first

This page lists the doses that appear in published ipamorelin research — and only that. It does not tell anyone what to take, because there is no approved human dose: ipamorelin is not a medicine, and its one human efficacy trial failed ^[3]. Think of this as a record of what scientists put into rats, ferrets, and a handful of human volunteers, written down with the species and the route so the numbers mean something. Where you see a dose, it belongs to a study — never to you. The popular CJC-1295 'stack' protocols traded in online communities have no peer-reviewed human dosing basis at all and are described here as anecdote, not recommendation ^[3]. Half-life, the routes researchers have used, and how the material is handled in the lab all live below, in third person, the way the literature reports them.

The doses studied, by species and route

Across the published record, the doses cluster by what each study was testing:

• Human pharmacokinetics: 4.21 to 140.45 nmol/kg intravenously over 15 minutes, as single doses, in eight healthy men ^[2].
• Human Phase 2 ileus trial: 0.03 mg/kg intravenously twice daily for up to 7 days, in 114 surgery patients ^[3].
• Rat bone-growth study: 18, 90, and 450 micrograms per day subcutaneously, divided three times daily, for 15 days ^[4].
• Rat chronic-dosing study: a 21-day subcutaneous course used to probe tolerance ^[7].
• Rat GH-under-steroid study: 0.4 to 1.6 mg/kg per day intravenously, four times daily ^[8].
• Ferret cachexia study (2024): 1 to 3 mg/kg intraperitoneally ^[5].

Notice the spread: nanomoles-per-kilogram in careful human pharmacology, milligrams-per-kilogram in rodents, and entirely different routes. These are not interchangeable, and none translate to a human protocol ^[3].

Half-life and the shape of the GH pulse

Ipamorelin is short-acting. In the human pharmacokinetic study, the terminal half-life was about 2 hours, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg ^[2]. The GH response it triggers is not a long plateau but a single discrete pulse, peaking roughly 40 minutes (0.67 hours) after dosing ^[2]. In rats, plasma clearance was reported to be roughly 5-fold lower than for GHRP-6 ^[2]. The practical research implication is simple: the molecule comes and goes quickly, and the GH effect it produces is a brief spike rather than a sustained elevation ^[2].

Routes researchers have used

Published ipamorelin work spans several routes, each tied to a purpose. Intravenous dosing carried the human pharmacokinetic and clinical-trial work and much rodent efficacy testing ^[2][3]. Subcutaneous dosing dominates the rodent bone and body-composition studies — and is also the route most community research use relies on, though without published human characterization ^[4]. Intranasal and intraperitoneal routes appear in rodent and ferret work ^[5]. Plain ipamorelin is not orally bioavailable; only engineered ipamorelin-derived analogs have shown meaningful oral absorption in animals ^[4]. The route always matters: a dose means nothing without the way it was delivered ^[2].

How much cjc-1295 ipamorelin should i take

There is no research-validated answer to 'how much cjc-1295 ipamorelin should i take,' and this site does not provide one. No peer-reviewed human trial has ever tested the CJC-1295-plus-ipamorelin combination at any dose for any outcome — the pairing is supported only by separate single-agent pharmacology ^[3][10]. The community subcutaneous 'stack' regimens circulated online have no controlled human dosing basis and are, by definition, anecdotal rather than evidence-based ^[3]. What the literature does document is single-agent data: ipamorelin's human doses were intravenous and given in a research setting ^[2], and CJC-1295's human GH and IGF-1 effects came from defined subcutaneous study doses in trials of that drug alone ^[10]. None of that constitutes a usage instruction.

How to reconstitute cjc-1295 ipamorelin 5mg

On 'how to reconstitute cjc-1295 ipamorelin 5mg': the research-supply literature describes ipamorelin as a lyophilized (freeze-dried) powder, supplied as the free base or acetate salt, that is reconstituted with bacteriostatic water for laboratory handling ^[2]. As a peptide it degrades with heat and repeated freeze-thaw cycles, so reconstituted solution is typically kept refrigerated ^[2]. These are general peptide-handling observations from the research-supply context, not a clinical preparation instruction and not a dosing protocol — and there is no validated human regimen for a CJC-1295/ipamorelin combination to prepare toward ^[3]. Any specific concentration or volume someone calculates is a research-handling choice outside the scope of any approved use ^[3].